Skip to main content

Commentaries

This list will be updated with all of our new commentaries including Comments, Editorials, Meeting reports, Opinions and Q&As. Commentaries in Genome Medicine are open access and therefore free to read and share.

Page 1 of 3

  1. Here, we report a lack of diversity in epigenome-wide association studies (EWAS) and DNA methylation (DNAm) data, discuss current challenges, and propose solutions for EWAS and DNAm research in diverse populat...

    Authors: Charles E. Breeze, Jason Y. Y. Wong, Stephan Beck, Sonja I. Berndt and Nora Franceschini
    Citation: Genome Medicine 2022 14:71
    Content type: Comment Published on:

  4. We discuss the current state of genomic medicine in Arab countries of the Middle East, a region with outsized contribution to Mendelian genetics due to inbreeding yet has poor representation in global variome ...

    Authors: Ahmad N. Abou Tayoun, Khalid A. Fakhro, Alawi Alsheikh-Ali and Fowzan S. Alkuraya
    Citation: Genome Medicine 2021 13:184
    Content type: Comment Published on:

  5. Ensuring accordance with principles of healthcare ethics requires improved communication of pathogen genomic data. This could include educating healthcare professionals in communicating pathogen genomic inform...

    Authors: Angeline S Ferdinand, Jane S Hocking, Justin T. Denholm, Benjamin P. Howden and Deborah A. Williamson
    Citation: Genome Medicine 2021 13:178
    Content type: Comment Published on:

  6. If each cancer cell produces on average more than one cancer cell, we see a net growth of the tumors and metastases and vice versa. We review recent clinical results for microsatellite stable metastatic colore...

    Authors: Devabhaktuni Srikrishna and Kris Sachsenmeier
    Citation: Genome Medicine 2021 13:120
    Content type: Comment Published on:

  7. The Global Alliance for Genomics and Health has approved a policy for the return of clinically actionable genomic research results, the first such policy approved by an international body. The policy acknowled...

    Authors: Anna C. F. Lewis, Bartha Maria Knoppers and Robert C. Green
    Citation: Genome Medicine 2021 13:115
    Content type: Comment Published on:

  14. Genomic studies of patients with COVID-19, or exposed to it, are underway to delineate host factors associated with variability in susceptibility, infectivity, and disease severity. Here, we highlight the ethi...

    Authors: Gail Geller, Priya Duggal, Chloe L. Thio, Debra Mathews, Jeffrey P. Kahn, Lisa L. Maragakis and Brian T. Garibaldi
    Citation: Genome Medicine 2020 12:95
    Content type: Comment Published on:

  15. Although the microbiome is established as an important regulator of health and disease, the role of viruses that inhabit asymptomatic humans (collectively, the virome) is less defined. While we are still chara...

    Authors: Fatemeh Adiliaghdam and Kate L. Jeffrey
    Citation: Genome Medicine 2020 12:66
    Content type: Comment Published on:

  17. Clinical whole-genome sequencing (WGS) offers clear diagnostic benefits for patients with rare disease. However, there are barriers to its widespread adoption, including a lack of standards for clinical practi...

    Authors: Christian R. Marshall, David Bick, John W. Belmont, Stacie L. Taylor, Euan Ashley, David Dimmock, Vaidehi Jobanputra, Hutton M. Kearney, Shashikant Kulkarni and Heidi Rehm
    Citation: Genome Medicine 2020 12:48
    Content type: Comment Published on:

  18. Clinical exome sequencing is frequently used to identify gene-disrupting variants in individuals with neurodevelopmental disorders. While splice-disrupting variants are known to contribute to these disorders, ...

    Authors: Stephan J. Sanders, Grace B. Schwartz and Kyle Kai-How Farh
    Citation: Genome Medicine 2020 12:36
    Content type: Comment Published on:

  19. The European Union (EU) initiative on the Digital Transformation of Health and Care (Digicare) aims to provide the conditions necessary for building a secure, flexible, and decentralized digital health infrast...

    Authors: F. M. Aarestrup, A. Albeyatti, W. J. Armitage, C. Auffray, L. Augello, R. Balling, N. Benhabiles, G. Bertolini, J. G. Bjaalie, M. Black, N. Blomberg, P. Bogaert, M. Bubak, B. Claerhout, L. Clarke, B. De Meulder…
    Citation: Genome Medicine 2020 12:18
    Content type: Opinion Published on:

  21. Personalized medicine requires the integration and processing of vast amounts of data. Here, we propose a solution to this challenge that is based on constructing Digital Twins. These are high-resolution model...

    Authors: Bergthor Björnsson, Carl Borrebaeck, Nils Elander, Thomas Gasslander, Danuta R. Gawel, Mika Gustafsson, Rebecka Jörnsten, Eun Jung Lee, Xinxiu Li, Sandra Lilja, David Martínez-Enguita, Andreas Matussek, Per Sandström, Samuel Schäfer, Margaretha Stenmarker, X. F. Sun…
    Citation: Genome Medicine 2019 12:4
    Content type: Comment Published on:

  22. Variants of uncertain significance represent a massive challenge to medical genetics. Multiplexed functional assays, in which the functional effects of thousands of genomic variants are assessed simultaneously...

    Authors: Hannah Gelman, Jennifer N. Dines, Jonathan Berg, Alice H. Berger, Sarah Brnich, Fuki M. Hisama, Richard G. James, Alan F. Rubin, Jay Shendure, Brian Shirts, Douglas M. Fowler and Lea M. Starita
    Citation: Genome Medicine 2019 11:85
    Content type: Opinion Published on:

  25. As the number of stroke survivors continues to increase, identification of therapeutic targets for stroke recovery has become a priority in stroke genomics research. The introduction of high-throughput genotyp...

    Authors: Julián N. Acosta, Stacy C. Brown and Guido J. Falcone
    Citation: Genome Medicine 2019 11:58
    Content type: Comment Published on:

  29. The expression of antigens that are recognized by self-reactive T cells is essential for immune-mediated tumor rejection by immune checkpoint blockade (ICB) therapy. Growing evidence suggests that mutation-ass...

    Authors: Claire Lhuillier, Nils-Petter Rudqvist, Olivier Elemento, Silvia C. Formenti and Sandra Demaria
    Citation: Genome Medicine 2019 11:40
    Content type: Opinion Published on:

  30. Personalized care of cancer patients undergoing treatment with immune checkpoint inhibitors will require approaches that can predict their susceptibility to immune-related adverse events. Understanding the rol...

    Authors: Zia Khan, Christian Hammer, Ellie Guardino, G. Scott Chandler and Matthew L. Albert
    Citation: Genome Medicine 2019 11:39
    Content type: Comment Published on:

  31. Recent sequencing studies on healthy skin and esophagus have found that, as we age, these tissues become colonized by mutant clones of cells carrying driver mutations in traditional cancer genes. This comment ...

    Authors: Inigo Martincorena
    Citation: Genome Medicine 2019 11:35
    Content type: Comment Published on:

  33. As epigenetic studies become more common and lead to new insights into health and disease, the return of individual epigenetic results to research participants, in particular in large-scale epigenomic studies,...

    Authors: Stephanie O. M. Dyke, Katie M. Saulnier, Charles Dupras, Amy P. Webster, Karen Maschke, Mark Rothstein, Reiner Siebert, Jörn Walter, Stephan Beck, Tomi Pastinen and Yann Joly
    Citation: Genome Medicine 2019 11:31
    Content type: Opinion Published on:

  34. The nature of the tumor antigens that are detectable by T cells remains unclear. In melanoma, T cells were shown to react against major histocompatibility complex (MHC)-associated peptides (MAPs) that are deri...

    Authors: Grégory Ehx and Claude Perreault
    Citation: Genome Medicine 2019 11:29
    Content type: Comment Published on:

    The Research to this article has been published in Genome Medicine 2019 11:28

  38. Genomic medicine has considerable potential to provide novel diagnostic and therapeutic solutions for patients who have molecularly complex diseases and who are not responding to existing therapies. To bridge ...

    Authors: Huan Zhang, Lars Klareskog, Andreas Matussek, Stefan M. Pfister and Mikael Benson
    Citation: Genome Medicine 2019 11:9
    Content type: Comment Published on:

  43. Only a small fraction of patients respond to the drug prescribed to treat their disease, which means that most are at risk of unnecessary exposure to side effects through ineffective drugs. This inter-individu...

    Authors: Monique G. P. van der Wijst, Dylan H. de Vries, Harm Brugge, Harm-Jan Westra and Lude Franke
    Citation: Genome Medicine 2018 10:96
    Content type: Opinion Published on:

  45. Telomere crisis is linked with many of the genomic alterations found in cancer genomes. A new understanding of how these alterations arise points towards an active role for innate immune sensors during crisis ...

    Authors: Patrick von Morgen and John Maciejowski
    Citation: Genome Medicine 2018 10:89
    Content type: Comment Published on:

  47. Immunotherapy has revolutionized the management of numerous cancers; however, a substantial proportion that initially respond subsequently acquire means of immune escape and relapse. Analysis of recent clinica...

    Authors: J. Bryan Iorgulescu, David Braun, Giacomo Oliveira, Derin B. Keskin and Catherine J. Wu
    Citation: Genome Medicine 2018 10:87
    Content type: Comment Published on: